All In Biotech

Drug Trial Radar · NCT07764237

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

A Phase 1, Randomized, Open-label Staggered Dose-escalation and Observer-blind Expansion Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Multicomponent Vaccine mRNA-1365 (Profile 2 [RSV and hMPV]) in Healthy Adults ≥60 Years of Age

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Aug 11, 2026

Primary completion

Jul 20, 2027

Study completion Jul 20, 2027

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Aug 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups

Conditions

  • Respiratory Syncytial Virus (RSV)
  • Human Metapneuomovirus (hMPV)

Interventions

  • mRNA-1365 (Profile 2)Biological

    Sterile liquid for injection

  • mRNA-1345 (Profile 1)Biological

    Sterile liquid for injection

  • mRNA-1345 (Profile 3)Biological

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 7 (the day of study intervention and 6 subsequent days)
  2. Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 28 (the day of study intervention and 27 subsequent days)
  3. Number of Participants with Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), Any AEs Leading to Study Discontinuation, and AEs of Special Interest (AESIs)Time frame: Up to End of Study (EOS) (Day 181)

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Diex Recherche Quebec

    Québec, Quebec, Canada · Recruiting

  • Diex Recherche Victoraville

    Victoriaville, Quebec, Canada · Recruiting

  • Royal Free Hospital, NHS

    London, United Kingdom · Not yet recruiting

  • Guys and St. Thomas Hospital, NHS

    London, United Kingdom · Not yet recruiting

  • St. George University Hospital, NHS

    London, United Kingdom · Not yet recruiting

  • Royal Victoria Infirmary, NHS

    Newcastle, United Kingdom · Not yet recruiting

  • MAC Clinical Research

    Manchester, Greater Manchester, United Kingdom · Not yet recruiting

  • Southampton General Hospital, NHS

    Southampton, Hampshire, United Kingdom · Not yet recruiting

  • Norfolk and Norwich University Hospital, NHS

    Norwich, Norfolk, United Kingdom · Not yet recruiting

  • University Hospital Birmingham, NHS

    Birmingham, West Midlands, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.